Aruna Bio is developing proprietary neural exosomes that can cross the blood‑brain barrier to treat a range of neurodegenerative disorders. The company is advancing exosomes both as standalone therapeutics and as delivery vehicles for RNA, oligonucleotides, proteins and other cargos. It leverages a proprietary exosome and manufacturing platform to create synergistic therapies and enhance delivery to the central nervous system. Aruna Bio is working with top‑tier pharmaceutical companies to explore both therapeutic applications and delivery capabilities. The company plans to submit its first Investigational New Drug (IND) application to the FDA late next year. A recently closed financing is intended to support the business through mid‑2022. ArunA Bio develops a proprietary neural exosome delivery platform and a pipeline of neural exosome therapies targeting neurodegenerative diseases such as ALS, Huntington’s disease and stroke. The company leverages neural exosomes’ ability to cross the blood–brain barrier and to provide anti-inflammatory, neuroprotective and neuroregenerative effects, and to deliver therapeutic payloads including siRNAs and antibodies. Proceeds from the recent financing will be used to further validate therapeutic benefits, advance payload delivery capabilities, and expand proprietary manufacturing to meet regulatory requirements. ArunA Bio plans to use data from planned studies to support submission of its first pre‑IND package to the U.S. FDA in the upcoming months. The company also intends to hire key personnel and seek partnerships with pharmaceutical and biotech companies in the neurodegenerative space. ArunA maintains research and manufacturing activities in Athens, Georgia, and has established an office in Research Triangle Park, North Carolina. ArunA Bio develops a neural exosome therapeutic platform whose proprietary neural exosomes inherently cross the blood–brain barrier and enable drugs and drug combinations to target diseased cells in neurological disorders. The company emphasizes scalable manufacturing of exosomes and cites more than 13 years of experience manufacturing human neural stem cell lines. ArunA says its exosomes can deliver functional proteins, mRNA transcripts, miRNA and small molecules and play a central role in intracellular communication and cellular repair. The company plans to use recent financing to further develop its neural exosome platform and manufacturing processes across a broad range of neurological disorders. Steven Stice, Ph.D., is co-founder and serves as chief executive and chief scientific officer. ArunA Bio is based in Athens, Ga. The company has secured new external funding to advance its platform and manufacturing capabilities.

Total raised

$29M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2021